CYP3A4 and acute myeloid leukemia: In conclusion, plasma VEN levels measured in the early phase of AML treatment when a strong CYP3A4 as PCZ was added show a substantial inter-individual pharmacokinetic variability and a delay of steady state achievement compared to the schedule without PCZ.